We are live on ! Find out more
XRTX

XORTX Therapeutics

5 hedge funds and large institutions have $136K invested in XORTX Therapeutics in 2022 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

178% more capital invested

Capital invested by funds: $49K → $136K (+$87K)

67% more funds holding

Funds holding: 35 (+2)

0% more ownership

Funds ownership: 0%0% (+0%)

Holders
5
Holders Change
+2
Holders Change %
+66.67%
% of All Funds
0.08%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
2
Increased
2
Reduced
Closed
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
Susquehanna International Group
1
Susquehanna International Group
Pennsylvania
$58K +$47.5K +72 New
CIBC World Market
2
CIBC World Market
Ontario, Canada
$44K
VF
3
Virtu Financial
New York
$24K +$19.8K +30 New
UBS Group
4
UBS Group
Switzerland
$7K +$3.96K +6 +200%
Royal Bank of Canada
5
Royal Bank of Canada
Ontario, Canada
$3K +$1.98K +3 +300%

XRTX Hedge Fund Activity: Q1 2022 in Review

5 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in XORTX Therapeutics (XRTX) for Q1 2022, worth a combined $136K — up 178% from $49K a quarter earlier.

Buyers outnumbered sellers: 2 funds opened new XRTX positions and 0 closed out — a net gain of 2 holders — while 2 added to existing stakes and 0 trimmed.

The largest buyer was Susquehanna International Group, opening a new position worth an estimated $47.5K.

  • 5 institutional investors held XORTX Therapeutics (XRTX) as of Q1 2022, up from 3 in Q4 2021.
  • Funds reported $136K of XORTX Therapeutics stock for Q1 2022, up 178% quarter-over-quarter.
  • 2 funds opened new XORTX Therapeutics positions in Q1 2022 and 0 closed out, a net change of +2 holders.
  • The largest XORTX Therapeutics buyer in Q1 2022 was Susquehanna International Group, an estimated $47.5K added.

Based on aggregated 13F filings for Q1 2022.